Navigation Links
Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Date:8/18/2008

WALTHAM, Mass., Aug. 18 /PRNewswire/ -- Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced today the successful completion of its Phase 1b randomized controlled multi-dose safety and pharmacokinetics study of LT-NS001, the Company's proprietary naproxen prodrug. The study, which was conducted from December, 2007 through July, 2008 in normal adult volunteers, showed that LT-NS001 was well-tolerated by the recipients. Moreover, when the subjects in the study were dosed twice daily with LT-NS001 for seven days, plasma concentrations of naproxen were within the therapeutic range.

LT-NS001 is a prodrug, which is converted in the bloodstream into naproxen, a non-steroidal anti-inflammatory drug (NSAID). Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class. In pre-clinical studies in rats and dogs, LT-NS001 was shown to cause significantly less damage to the gastrointestinal tract than equivalent doses of naproxen. LT-NS001 has completed pre-clinical toxicology testing and was previously evaluated in a Phase 1a randomized controlled single-dose and multiple-dose study and shown to be well tolerated.

"The robust pre-clinical data package for LT-NS001 suggests that this novel compound will provide patients with a drug that combines the efficacy and cardiovascular safety of naproxen while substantially decreasing the risk for gastrointestinal ulceration," said Dr. Mitchell Fink, the President and CEO of Logical Therapeutics, Inc. "The results from our recently completed P1b study of LT-NS001 are very encouraging, because they show that administration of the pro-drug leads to clinically useful circulating levels of naproxen."

Physicians and patients have accumulated more than 30 years of experience with naproxen, which is widely prescribed to treat pain and other signs and symptoms of inflammation caused by chronic conditions, such as osteoarthritis and rheumatoid arthritis. Despite its considerable efficacy and its good cardiovascular safety profile, naproxen, like most NSAIDs, can cause serious, even life-threatening, gastrointestinal complications. A safer alternative would fulfill a significant unmet medical need.

The company expects to begin enrolling subjects in its next clinical study of LT-NS001 later this year.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company based in Waltham, Massachusetts. Logical Therapeutics is developing drugs to treat a variety of medical conditions that are associated with excessive inflammation, including osteoarthritis and rheumatoid arthritis. For more information on Logical Therapeutics, visit the company's website at http://www.logicaltherapeutics.com or send an email to info@logicaltherapeutics.com


'/>"/>
SOURCE Logical Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
6. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
7. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
8. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
9. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
10. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
11. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... that it has joined the Human Vaccines Project, a public-private partnership to ... cancer. , The Human Vaccines Project brings together leading pharmaceutical and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual ... is expecting to fill more than 100 tables for its annual event, which ...
Breaking Biology Technology:
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 ... innovative sensor-based diagnostic products, today announced the closing of a ... existing investors.  Proceeds from the financing will be used to ... hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has ...
Breaking Biology News(10 mins):